- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02241772
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
February 12, 2015 updated by: Xention Ltd
A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.
Study Overview
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Herlev, Denmark, DK-2730
- Herlev Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female (of non-child bearing potential) subjects with elevated Lp(a) levels
Exclusion Criteria:
- Clinically significant medical history
- Abnormal laboratory results (other than lipid levels) or vital signs
- Receiving any other drug therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10mg TA-8995
10mg TA-8995 once daily
|
|
Experimental: 2.5mg TA-8995
2.5mg TA-8995 once daily
|
|
Placebo Comparator: Placebo to TA-8995
Placebo to TA-8995 once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the change from baseline in (Lp(a) levels after 12 weeks of treatment with TA-8995.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
February 1, 2015
Study Registration Dates
First Submitted
August 20, 2014
First Submitted That Met QC Criteria
September 12, 2014
First Posted (Estimate)
September 16, 2014
Study Record Updates
Last Update Posted (Estimate)
February 16, 2015
Last Update Submitted That Met QC Criteria
February 12, 2015
Last Verified
October 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- TA-8995-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elevated Lp(a)
-
Silence Therapeutics plcMedpace, Inc.CompletedDyslipidemias | Hyperlipidemias | Elevated Lp(a)United States, Australia, United Kingdom, Netherlands
-
Novartis PharmaceuticalsNot yet recruitingElevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
-
University of IoanninaRecruitingInsight Into the Prevalence of Elevated Lp(a) Among Greek Medical StudentsGreece
-
Eli Lilly and CompanyRecruitingElevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)United States, Australia, Belgium, Spain, Japan, Canada, Argentina, China, Italy, Netherlands, France, Germany, Taiwan, Korea, Republic of, Brazil, Denmark, Hungary, Israel, Austria, Mexico, Romania, United Kingdom, Greece, Poland, Czechia and more
-
Technische Universität DresdenKaneka Pharma Europe N.V.RecruitingLipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaGermany
-
Ionis Pharmaceuticals, Inc.CompletedElevated Lipoprotein(a)Netherlands, United Kingdom, Denmark, Germany, Canada
-
Ionis Pharmaceuticals, Inc.Akcea TherapeuticsCompleted
-
Changi General HospitalNot yet recruitingCardiovascular Diseases | Hypercholesterolemia | Lipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaSingapore
-
AmgenCompletedElevated Serum Lipoprotein(a)Hong Kong
-
Charite University, Berlin, GermanyUnknownElevated Lipoprotein(a) LevelsGermany
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States